Table 4 The Cox proportional hazards analysis of RFS according to the EGFR mutation status.

From: PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC

EGFR mutation

N

Recurrence

N (%)

Unadjusted HR

(95% CI), P

Adjusted HRa

(95% CI), P

Wild-type

181

32

(17.7)

Reference

Reference

Major mutationb

79

4

(5.06)

0.26

(0.09–0.74), 0.01

0.42

(0.14–1.25), 0.12

Minor mutationc

20

3

(15.0)

0.77

(0.23–2.51), 0.66

0.63

(0.18–2.15), 0.46

  1. RFS recurrence-free survival, EGFR epidermal growth factor receptor gene, HR hazard ratio, CI confidence interval, PD-L1 programmed death-ligand1, Ex21 exon 21 L858R mutation, Ex19 exon19 deletion mutation.
  2. aAdjusted by PD-L1 expression status, pathological stage, histological type and adjuvant chemotherapy.
  3. bEx21 or Ex19.
  4. cDefined as all mutations except Ex21 and Ex19.
Back to article page